Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interleukin-3: a preclinical study].

P Valent1, K Geissler, P Bettelheim

  • 1I. Medizinische Universitätsklinik, Wien.

Wiener Klinische Wochenschrift
|October 13, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network.

Annals of hematology·2020
Same author

[German Guideline for Idiopathic Pulmonary Fibrosis].

Pneumologie (Stuttgart, Germany)·2020
Same author

[German Guideline for Idiopathic Pulmonary Fibrosis].

Pneumologie (Stuttgart, Germany)·2020
Same author

Laryngo- rhino- otologie·2018
Same author

Laryngo- rhino- otologie·2018
Same author

Differential regulation of PD-1 and its ligands in allergic asthma.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2017
Same journal

[Vaccination of immunocompromised individuals: Expert opinion - update 2026].

Wiener klinische Wochenschrift·2026
Same journal

Systematic review of clinical evidence for Kneipp medicine.

Wiener klinische Wochenschrift·2026
Same journal

Pelvic resections in primary sarcomas : Surgical outcomes and survival analysis of 75 patients.

Wiener klinische Wochenschrift·2026
Same journal

Jungmediziner*innen am Start: 11. Workshop für den medizinischen Nachwuchs.

Wiener klinische Wochenschrift·2026
Same journal

Stellungnahme der ÖGP zur geplanten Gesetzesnovelle zum Nichtraucherschutzgesetz.

Wiener klinische Wochenschrift·2026
Same journal

MUW researcher of the month: Dr. Moritz Schaefer.

Wiener klinische Wochenschrift·2026
See all related articles

Recombinant human interleukin-3 (rhIL-3) is a potent growth factor for hematopoietic stem cells, promoting their self-renewal and differentiation. This cytokine shows promise for stem cell transplantation and treating cytopenic disorders.

Area of Science:

  • Hematology and Immunology
  • Molecular Biology and Genetics

Context:

  • Recombinant hemopoietic cytokines are increasingly utilized in clinical hematology.
  • Preclinical evaluation of novel cytokines is crucial for therapeutic development.

Purpose:

  • To characterize the biological spectrum of recombinant human interleukin-3 (rhIL-3).
  • To investigate the in vitro and in vivo effects of rhIL-3 on hematopoietic stem cells and mature blood cells.
  • To identify potential clinical applications and adverse effects of rhIL-3.

Summary:

  • Interleukin-3 acts as a potent growth factor for hematopoietic stem cells, inducing self-renewal and differentiation.
  • rhIL-3 promotes terminal differentiation of basophilic and eosinophilic granulocytes and activates mature basophils.
  • In vivo studies in rhesus monkeys confirmed stem cell pool expansion and increased basophil and eosinophil counts, with observed side effects including elevated histamine and skin rash.

Related Experiment Videos

Impact:

  • Provides evidence for IL-3's role in stem cell regulation, supporting its potential in stem cell transplantation and cytopenic disorder treatment.
  • Highlights potential adverse effects related to the stimulation of allergic effector cells, necessitating careful clinical monitoring.
  • Establishes rhIL-3 as a significant cytokine with broad effects on hematopoiesis and immune cell function.